anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study aims to explore the application of ultrasonic scattering imaging technology in patients after anterior cruciate ligament (ACL) reconstruction and in patients with shoulder musculoskeletal disorders. Ultrasonography is a convenient, real-time, non-invasive, and portable imaging tool commonly used by clinicians for the diagnosis of musculoskeletal system disorders. However, the interpretation of ultrasound images can be affected by factors such as operator experience, probe orientation, machine type, and parameter settings, and most diseases cannot be quantified. Nakagami imaging, based on the backscattering statistical distribution model, is a quantitative assessment method that can reduce subjective human judgment. It extracts the basic physical properties of tissues based on the interaction between ultrasound and tissue microstructure. The Nakagami distribution is an effective model for describing tissue inverse scattering envelope statistics, which can identify tissue ultrasound image features and classify the examined tissue by comparing it with the specified envelope-related scattering conditions.

ACL reconstruction surgery is a commonly performed procedure. Postoperative issues often include joint stiffness, loss of neuromuscular control, muscle mass loss, and muscle strength decline. Changes in muscle quality and volume are associated with a decrease in thigh muscle strength. Both MRI and ultrasound can be used to assess changes in muscle volume and quality. Soft tissue injuries around the shoulder and ankle joints are common in the field of sports medicine. Ultrasound is commonly used to assess the severity of injuries to soft tissues such as the rotator cuff tendons/muscles and surrounding ligaments of the shoulder, as well as the medial and lateral ligament complexes of the ankle. Preliminary results of this study show that Nakagami scattering imaging can visually distinguish layers within normal tendons. The investigative team hypothesizes that ultrasonic Nakagami scattering imaging can provide a method for visualizing and subsequent quantitative analysis of suspected soft tissue lesions in patients after ultrasound scanning, with the goal of achieving standardized diagnostic parameters for soft tissue lesions.

The results of this project may enhance the diagnostic efficacy of musculoskeletal ultrasound for use in musculoskeletal diseases. If successful, it could lead to earlier diagnosis and treatment for these patients, reducing the socioeconomic losses associated with work and competition. Academically, it would establish the institution and team as world leaders in the application of ultrasound inverse scattering imaging technology.
BACKGROUND: Patients with acute upper gastrointestinal bleeding (UGIB) are made NPO prior to endoscopy. It is standard practice in those found to have low risk lesions to immediately resume a usual diet. Here, we evaluated refeeding practices in hospitalized patients with UGIB after endoscopy.
METHODS: In this retrospective single-center cross-sectional study, we examined patients over the age of 18 with acute UGIB and low risk or no endoscopic lesion(s). Appropriate refeeding was categorically defined as resuming normal diet ≤ 4 h post-endoscopy.
RESULTS: Of 230 patients (mean age, 62 years; 57% female) with acute UGIB and low-risk lesions or no lesion(s), 96 [41% (95% CI: 35% to 48%)] received their usual diet within 4 h after EGD. For the remaining 134 patients, refeeding was delayed on average from 13 (NPO until regular diet) to 31 (NPO until liquid diet, then regular diet) hours. Baseline clinical features were identical in patients who received their regular diet within 4 h after EGD and those who did not. Hospital length of stay was shorter in patients receiving usual diets promptly (5.3 days vs. 6.4 days, p = 0.03). Patients in an ICU at the time of their endoscopy had a statistically significantly higher probability of not being refed appropriately [OR 2.371, 95% CI 1.191-4.722).
CONCLUSIONS: Inappropriate dietary restrictions are frequent in patients with UGIB caused by low risk lesions. This delay in refeeding leads to increased length of hospital stay - suggesting that appropriate refeeding is an opportunity to improve patient care.
The duration of placebo patch wear was 9 hours per day. A new patch was applied each morning upon awakening.
Lymphatic aging represented by cellular and functional changes, is involved in increased geriatric disorders, but the intersection between aging and lymphatic modulation is less clear. Lymphatic vessels play an essential role in maintaining tissue fluid homeostasis, regulating immune function, and promoting macromolecular transport. Lymphangiogenesis and lymphatic remodeling following cellular senescence and organ deterioration are crosslinked with the progression of some lymphatic-associated diseases, e.g., atherosclerosis, inflammation, lymphoedema, and cancer. Age-related detrimental tissue changes may occur in lymphatic vessels with diverse etiologies, and gradually shift towards chronic low-grade inflammation, so-called inflammaging, and lead to decreased immune response. The investigation of the relationship between advanced age and organ deterioration is becoming an area of rapidly increasing significance in lymphatic biology and medicine. Here we highlight the emerging importance of lymphangiogenesis and lymphatic remodeling in the regulation of aging-related pathological processes, which will help to find new avenues for effective intervention to promote healthy aging.
BACKGROUND: Physical activity (PA) is essential and effective for chronic heart failure (CHF) patients. A greater understanding of the longitudinal change in PA and its influencing factors during the postdischarge transition period may help create interventions for improving PA. The aims of this study were (1) to compare the change in PA, (2) to examine the influencing factors of PA change, and (3) to verify the mediating pathways between influencing factors and PA during the postdischarge transition period in CHF patients.
METHODS: A total of 209 CHF patients were recruited using a longitudinal study design. The Chinese version of the International Physical Activity Questionnaire (IPAQ), Patient-reported Outcome Measure for CHF (CHF-PRO), and the Chinese version of the Tampa Scale for Kinesiophobia Heart (TSK-Heart) were used to assess PA, CHF-related symptoms, and kinesiophobia. The IPAQ score was calculated (1) at admission, (2) two weeks after discharge, (3) two months after discharge, and (4) three months after discharge. Two additional questionnaires were collected during admission. Generalized estimating equation (GEE) models were fitted to identify variables associated with PA over time. We followed the STROBE checklist for reporting the study.
RESULTS: The PA scores at the four follow-up visits were 1039.50 (346.50-1953.00) (baseline/T1), 630.00 (1.00-1260.00) (T2), 693.00 (1-1323.00) (T3) and 693.00 (160.88-1386.00) (T4). The PA of CHF patients decreased unevenly, with the lowest level occurring two weeks after discharge, and gradually improving at two and three months after discharge. CHF-related symptoms and kinesiophobia were significantly associated with changes in PA over time. Compared with before hospitalization, an increase in CHF-related symptoms at two weeks and two months after discharge was significantly associated with decreased PA. According to our path analysis, CHF-related symptoms were positively and directly associated with kinesiophobia, and kinesiophobia was negatively and directly related to PA. Moreover, CHF-related symptoms are indirectly related to PA through kinesiophobia.
CONCLUSION: PA changed during the postdischarge transition period and was associated with CHF-related symptoms and kinesiophobia in CHF patients. Reducing CHF-related symptoms helps improve kinesiophobia in CHF patients. In addition, the reduction in CHF-related symptoms led to an increase in PA through the improvement of kinesiophobia.
TRIAL REGISTRATION: The study was registered in the Chinese Clinical Trial Registry (11/10/2022 ChiCTR2200064561 retrospectively registered).
Anastomotic leak (AL) after colorectal surgery represents a major clinical problem observed in a range from 2 to 7% of patients, rising up to 14% in low colorectal resections, and even to 26% in some older reports.1-3 Enhanced recovery after surgery (ERAS) programs are nowadays proven to reduce postoperative complications in up to 50% of cases, fasten recovery and shorten length of stay.4-5 These fast-track protocols demand very early patient discharge but this might be potentially associated with an increased risk of delayed diagnosis and treatment of AL occurring after patient discharge. Hence, there is a strong need of an additional tool to early diagnose anastomotic leak, prior patient discharge. Serum procalcitonin (PCT), is a 116 amino-acids protein produced by C-cells of the thyroid gland. PCT baseline levels are low (\<0.1 ng/ml), but increase significantly in patients with severe bacterial infections. Therefore, PCT levels are used to monitor the course and prognosis of systemic bacterial infections and to tailor the therapeutic interventions more efficiently.6-7 Furthermore, PCT could serve as an early predictive marker for the clinical course of septic complications after abdominal surgery.8-9 The aim of our study is to demonstrate if PCT is a more sensible, specific and reliable biomarker of anastomotic leak (AL) than CRP and WBC and if PCT is \< 5 ng/ml in 5th POD might be safely added as an additional criteria of early discharge in ERAS protocols.

All patients undergoing colorectal surgery in our centre, either electively or in emergency setting, are recruited. In all cases white blood count (WBC), C-reactive protein (CRP) and PCT levels are measured in 1st, 3rd and 5th postoperative day (POD). Patients' characteristics (age, sex, renal function, comorbidities), tumor localization, type of operation, intra and postoperative complications and their management, reinterventions, length of hospital stay are recorded. Inclusion criteria are: patients undergoing all different kinds of colorectal surgery (from right colectomies to low anterior resection), either in elective or emergent setting, either for cancer or benign disease (ex diverticular disease) with an anastomosis being performed (ileo-colic, colo-colic, or colo-rectal). Exclusion criteria are: age \< 18 years, pregnant women, patients undergoing abdomino-perineal resection or other kinds of colorectal-surgery without an anastomosis being performed. A written informed consent is obtained from all patients. The study is approved by our institution's Ethical Committee.
An intelligent ventilator system and operating method thereof are provided. The system includes a ventilator and an input system. The ventilator includes an alarm system, a monitoring system, a communication unit, and a ventilator control system, where the ventilator is configured to apply respiratory treatment to a patient. The input system is configured to input the patient's parameters and treatment requirements to realize recordings of original data of a designed treatment plan. The ventilator control system calculates target data needed by the patient and design the treatment plan, and to control the ventilator. The communication unit is configured for data communication between the input system and the ventilator control system to realize transfer of data from the input system to the ventilator control system. The monitoring system is configured for real-time monitoring of patients, and the alarm system is configured to alarm in time according to the patient's urgency.
Acetaminophen (APAP)-induced liver injury is one of the most prevalent causes of acute liver failure (ALF). We assessed the role of the bone morphogenetic protein (BMP) type I receptors ALK2 and ALK3 in APAP-induced hepatotoxicity. The molecular mechanisms that regulate the balance between cell death and survival and the response to oxidative stress induced by APAP was assessed in cultured human hepatocyte-derived (Huh7) cells treated with pharmacological inhibitors of ALK receptors and with modulated expression of ALK2 or ALK3 by lentiviral infection, and in a mouse model of APAP-induced hepatotoxicity. Inhibition of ALK3 signalling with the pharmacological inhibitor DMH2, or by silencing of ALK3, showed a decreased cell death both by necrosis and apoptosis after APAP treatment. Also, upon APAP challenge, ROS generation was ameliorated and, thus, ROS-mediated JNK and P38 MAPK phosphorylation was reduced in ALK3-inhibited cells compared to control cells. These results were also observed in an experimental model of APAP-induced ALF in which post-treatment with DMH2 after APAP administration significantly reduced liver tissue damage, apoptosis and oxidative stress. This study shows the protective effect of ALK3 receptor inhibition against APAP-induced hepatotoxicity. Furthermore, findings obtained from the animal model suggest that BMP signalling might be a new pharmacological target for the treatment of ALF.
The minimum O2 needed to fuel the demand of aquatic animals is commonly observed to increase with temperature, driven by accelerating metabolism. However, recent measurements of critical O2 thresholds ("Pcrit") reveal more complex patterns, including those with a minimum at an intermediate thermal "optimum". To discern the prevalence, physiological drivers, and biogeographic manifestations of such curves, we analyze new experimental and biogeographic data using a general dynamic model of aquatic water breathers. The model simulates the transfer of oxygen from ambient water through a boundary layer and into animal tissues driven by temperature-dependent rates of metabolism, diffusive gas exchange, and ventilatory and circulatory systems with O2-protein binding. We find that a thermal optimum in Pcrit can arise even when all physiological rates increase steadily with temperature. This occurs when O2 supply at low temperatures is limited by a process that is more temperature sensitive than metabolism, but becomes limited by a less sensitive process at warmer temperatures. Analysis of published species respiratory traits suggests that this scenario is not uncommon in marine biota, with ventilation and circulation limiting supply under cold conditions and diffusion limiting supply at high temperatures. Using occurrence data, we show that species with these physiological traits inhabit lowest O2 waters near the optimal temperature for hypoxia tolerance and are restricted to higher O2 at temperatures above and below this optimum. Our results imply that hypoxia tolerance can decline under both cold and warm conditions and thus may influence both poleward and equatorward species range limits.
FIELD: medicine. SUBSTANCE: method involves setting biological sample in contact with the first polypeptide reagent containing type-specific epitope, showing specificity for the first type of hepatitis C virus and/or epitope of a cluster-specific epitope showing specificity for the first type of hepatitis C virus cluster or to antibody sets showing specificity for the mentioned epitopes. The epitopes are selected from epitopes localized between amino acid residues 67 and 84, 1689 and 1718, and 2281 and 2313 HCV-1 or homologous areas of other types of HCV. Polypeptide set has polypeptides containing amino acid residues of type-specific or cluster-specific HCV epitopes. EFFECT: enhanced effectiveness of approach based on immunological methods. 11 cl, 4 dwg, 17 tbl
A drug for preventing or treating heart diseases which comprises an expression vector containing CD9 gene as the active ingredient. In the present invention, the term “heart diseases” means diseases causative of heart failure, ischemic heart diseases, cardiomyopathy, hypertensive heart diseases, valvular disease, congenital heart diseases, mayocarditis, arrhythmia and diseases associated with cardiac hypertrophy and/or tachycardia. In the present invention, the expression vector is a viral vector or a non-viral vector. A method for preventing or treating heart diseases which comprises expressing the CD9 gene in the heart. In the present invention, the prevention or the treatment is carried out by a gene therapy of transferring the CD9 gene. In the gene therapy, use is made of a drug comprising an expression vector containing the CD9 gene as the active ingredient.
PURPOSE:An antiviral agent, containing an oligodeoxynucletide or polydeoxynucleotide. CONSTITUTION:An antiviral agent containing an oligodeoxynucletide or a polydeoxynucleotide equal to a partial structure of DNA sequence capable of forming a hybrid on messenger RNA ocurring in multiplication of virus. A solution, injection, suppository, etc. may be used as the dosage form. The antiviral agent can target all pathogenic viruses of influenza, leukemia, dengue disease, hydrophobia, hepatitis, measles, encephalitis, and polio, is effective for remedying and preventing various diseases caused by animal and vegetable viruses. The deoxynucleotide has no influence on existence of normal cell and also has no influence on its multiplication ability.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely, immunology and infectious diseases, and can be used to treat an infection caused by a causative agent or pathogens with multiple drug resistance by carrying out personified phage therapy. For this purpose, select a bacteriophage or bacteriophages in two stages, determining the sensitivity of the target bacteria isolated from the patient to individual strains of virulent phages. In the first stage, use a spot test on a dish with a bacterial lawn sown on a dense nutrient medium containing 1.5–2 % agar, selecting phage or phages, under the influence of which there was a complete or partial lysis of the bacterial lawn or in the area of the applied spot there are separate negative colonies. In the second stage, apply the selected phage or phage drops of 10–100 mcl over the frozen second layer of the agar medium to a cup or petri dish, with the first layer being applied with 1.5–2 % nutrient agar, on which after its solidification by a second layer, a 0.7 % agar medium containing a bacterial culture isolated from the patient is applied. For application, use bacteriophages in a titer providing a multiplicity of infection from 0.01 to 1, taking into account the titer of the target bacterium sown from the infection site; select a phage or phages, under the influence of which the formation of individual negative colonies or the drainage lysis of the bacterial culture occurred, the results in the first and second stages are taken into account after incubating the plates at 37 °C for 18 hours. Then, by means of an enzyme immunoassay, determine the presence of IgG antibodies to the selected phage or phages in the patient's serum, after which perform the neutralization reactions, confirming the neutralizing properties of the antibodies found, and phages or phages are selected to which the patient lacks IgG antibodies that have confirmed neutralizing properties. Further, considering the localization of the infectious process and the pharmacokinetics of the selected phage or phages, determine at least one of the following routes of administration: per os, per rectum, inhalation, topically and corresponding to this route of administration, a dosage form, ensuring the preservation of bacteriophages in the focus of infection in the titer is no more than two orders of magnitude lower than the original, contained in the drug used in the patient, during the entire period of isolation from the focus of infection of the target bacterium and at least 24–48 hours after its elimination.EFFECT: use of this method allows for effective phagotherapy of infections caused by pathogens with multiple drug resistance, by a personified selection of the bacteriophage strain, the establishment of individual doses of the drug administered, and also taking into account the antiphagic immune response of the patient.3 cl, 4 ex
OBJECTIVE: A significant proportion of patients with advanced heart failure present with dilated left ventricles and functional mitral regurgitation. These patients currently have limited treatment options. The MitraClip device (Abbott) has benefited only patients with smaller left ventricles (end-diastolic dimension <70 mm), whereas those with larger left ventricles did not benefit. A possible explanation is correcting functional mitral regurgitation alone may not adequately reduce the wall stresses of a dilated left ventricle. We have developed a beating-heart device that not only approximates the papillary muscles to reduce functional mitral regurgitation but also modifies the left ventricle size and shape to reduce wall stress.
METHODS: Yorkshire swine (n = 16) had a myocardial infarction induced by permanent occlusion of the left circumflex with intracoronary ethanol. Three months later, the animals developed heart failure and moderate or greater functional mitral regurgitation. Through a transapical approach, the new device was implanted under echocardiography guidance to reshape the left ventricle and correct functional mitral regurgitation. The acute impact of this approach on the mitral valve and left ventricle was assessed with echocardiography and invasive hemodynamics.
RESULTS: After reshaping, echocardiography showed a decrease in end-diastolic volume by 36.3 ± 30.5 mL (P < .001), a decrease in sphericity index by 0.143 ± 0.087 (P < .001), and an increase in ejection fraction of 5.90% ± 6.38% (P < .01). Mitral valve tenting area was reduced by 39.29 ± 33.66 mm2 (P < .001), coaptation length was increased by 2.12 ± 1.02 mm (P < .001), and posterior excursion angle was improved by 9.07° ± 9.14° (P < .01), resulting in functional mitral regurgitation reduction.
CONCLUSIONS: Correction of functional mitral regurgitation with favorable changes in mitral valve geometry and reduction in left ventricle geometry is possible with the proposed device.
The invention provides for a method of operating a magnetic resonance system for acquiring magnetic resonance data (152) from a phantom (124) within a measurement (zone 108). The phantom comprises a known volume of at least one predetermined substance ((128), 130). The method comprises the step of acquiring (300) the magnetic resonance data by controlling the magnetic resonance system with pulse sequence instructions (150). The pulse sequence instructions cause the magnetic resonance system to acquire the magnetic resonance data according to a magnetic resonance fingerprinting technique. The pulse sequence instructions specify a train of pulse sequence repetitions. Each pulse sequence repetition has a repetition time chosen from a distribution of repetition times. Each pulse sequence repetition comprises a radio frequency pulse chosen from a distribution of radio frequency pulses. The distribution of radio frequency pulses cause magnetic spins to rotate to a distribution of flip angles. Each pulse sequence repetition comprises a sampling event where the magnetic resonance signal is sampled for a predetermined duration at a sampling time before the end of the pulse sequence repetition. The method further comprises determining (302) one or more performance degradation conditions of the magnetic resonance system by comparing the magnetic resonance data with a magnetic resonance fingerprinting dictionary (154). The magnetic resonance fingerprinting dictionary contains a listing of magnetic resonance signals for a set of system states in response to execution of the pulse sequence instructions for each of the at least one predetermined substance.
The intervention is composed of 4 parts: 1) a multidisciplinary team that recommends, develops, approves, monitors the components of the intervention and training? 2) monitoring of medication sedation risk using established scale 3) restriction of medication dispensing via enhanced technology 4) health professional training on multimodality pain management including complementary and alternative therapies.